# Dyne Therapeutics, Inc.: overview

DYN · Nasdaq · CIK 1818794 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/dyn.md) · [Financials](/companies/dyn/financials.md) · [Filings](/companies/dyn/filings.md) · [Insiders](/companies/dyn/insiders.md)

Revenue is not reported in this company’s XBRL financial statements.

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(0.96)](/filings/0001193125-25-266882.md) | not reported | [(1.05)](/filings/0001193125-26-215702.md) | [(0.97)](/filings/0001193125-26-323639.md) | [(0.76)](/filings/0001193125-25-266882.md) | not reported | [(0.73)](/filings/0001193125-26-215702.md) | [(1.08)](/filings/0001193125-26-323639.md) |
| Free cash flow | $m | [(74.9) d](/filings/0001193125-25-266882.md) | [(85.4) d](/filings/0001193125-26-084178.md) | [(107)](/filings/0001193125-26-215702.md) | [(94.8) d](/filings/0001193125-26-323639.md) | [(91.2) d](/filings/0001193125-25-266882.md) | [(112) d](/filings/0001193125-26-084178.md) | [(145)](/filings/0001193125-26-215702.md) | [(132) d](/filings/0001193125-26-323639.md) |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(2.93)](/filings/0000950170-23-005708.md) | [(3.23)](/filings/0000950170-25-028356.md) | [(3.95)](/filings/0001193125-26-084178.md) | [(3.37)](/filings/0001193125-26-084178.md) | [(3.47)](/filings/0001193125-26-084178.md) |
| Free cash flow | $m | [(123)](/filings/0000950170-23-005708.md) | [(157)](/filings/0000950170-25-028356.md) | [(189)](/filings/0001193125-26-084178.md) | [(295)](/filings/0001193125-26-084178.md) | [(405)](/filings/0001193125-26-084178.md) |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/dyn/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $275.5m | 12,404,330 |  | Added +704,460 |
| [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $266.6m | 11,997,738 |  | Not compared |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $248.9m | 11,207,000 |  | Added +2,298,020 |
| [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $247.4m | 13,647,376 |  | Not compared |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $165.6m | 7,458,263 |  | Added +804,517 |
| [Orbis Allan Gray Ltd](/funds/1663865.md) | 2026-06-30 | $155.6m | 7,006,542 |  | Added +244,311 |
| [Atlas Venture Life Science Advisors, LLC](/funds/1917529.md) | 2026-06-30 | $151.0m | 6,800,099 |  | Reduced −2,330,366 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $140.2m | 6,310,969 |  | Reduced −94,100 |
| [TCG Crossover Management, LLC](/funds/1839948.md) | 2026-06-30 | $102.5m | 4,615,144 |  | Unchanged |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $89.9m | 4,048,428 |  | Reduced −113,613 |

## Recent filings

[All 790 filings](/companies/dyn/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-29 | 20:10 ET | [8-K](/filings/0001818794-26-000009.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001818794-26-000009 |
| 2026-07-29 | 20:35 ET | [8-K](/filings/0001193125-26-323940.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-323940 |
| 2026-07-29 | 20:05 ET | [10-Q](/filings/0001193125-26-323639.md) | Quarterly report, period 2026-06-30 | 0001193125-26-323639 |
| 2026-07-22 | 21:19 ET | [8-K](/filings/0001193125-26-312571.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-312571 |
| 2026-07-20 | 11:35 ET | [8-K](/filings/0001193125-26-308343.md) | 8.01 Other events | 0001193125-26-308343 |
| 2026-06-22 | 20:15 ET | [8-K](/filings/0001818794-26-000005.md) | 5.02 Departure or appointment of officers or directors | 0001818794-26-000005 |
| 2026-06-17 | 11:35 ET | [8-K](/filings/0001818794-26-000003.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation | 0001818794-26-000003 |
| 2026-06-08 | 20:05 ET | [8-K](/filings/0001193125-26-261696.md) | 5.07 Shareholder vote results | 0001193125-26-261696 |
| 2026-06-03 | 11:35 ET | [8-K](/filings/0001193125-26-254597.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-254597 |
| 2026-05-11 | 11:35 ET | [8-K](/filings/0001193125-26-215720.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-215720 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-084178.md), filed Mar 2, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1818794
- Tickers: DYN
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.